This web only provides the extract of this article. If you want to read the figures and tables, please reference the PDF full text on Blackwell Synergy. Thank you.
- Review -
Extracellular quality control in the epididymis
Gail A. Cornwall, H. Henning von Horsten, Douglas Swartz, Seethal Johnson, Kim Chau, Sandra Whelly
Department of Cell Biology and Biochemistry, Texas Tech University Health Sciences Center, Lubbock, TX 79430, USA
Abstract
The epididymal lumen represents a unique extracellular environment because of the active sperm maturation
process that takes place within its confines. Although much focus has been placed on the interaction of epididymal
secretory proteins with spermatozoa in the lumen, very little is known regarding how the complex epididymal milieu
as a whole is maintained, including mechanisms to prevent or control proteins that may not stay in their native folded
state following secretion. Because some misfolded proteins can form cytotoxic aggregate structures known as
amyloid, it is likely that control/surveillance mechanisms exist within the epididymis to protect against this process
and allow sperm maturation to occur. To study protein aggregation and to identify extracellular quality control
mechanisms in the epididymis, we used the cystatin family of cysteine protease inhibitors, including cystatin-related
epididymal spermatogenic and cystatin C as molecular models because both proteins have inherent properties to
aggregate and form amyloid. In this chapter, we present a brief summary of protein aggregation by the amyloid
pathway based on what is known from other organ systems and describe quality control mechanisms that exist
intracellularly to control protein misfolding and aggregation. We then present a summary of our studies of
cystatin-related epididymal spermatogenic (CRES) oligomerization within the epididymal lumen, including studies suggesting
that transglutaminase cross-linking may be one mechanism of extracellular quality control within the epididymis.
(Asian J Androl 2007 July; 9: 500_507)
Keywords: epididymis; protein aggregation; extracellular quality control; cystatin; transglutaminase
Correspondence to: Dr Gail A. Cornwall, Department of Cell Biology and Biochemistry, Texas Tech University Health Sciences Center,
3601 4th Street, Lubbock, TX 79430, USA.
Tel/Fax: +1-806-743-2990
E-mail: gail.cornwall@ttuhsc.edu
DOI: 10.1111/j.1745-7262.2007.00309.x
1 Introduction
The tubular lumen of the epididymis is a unique extracellular environment distinct from many organ systems by
the active cell biological process that occurs within its luminal compartment. Within the epididymal lumen
spermatozoa acquire the functional capacities of motility and fertility as they migrate from the proximal to the distal region of
the tubule. This process is dependent on not only the interaction of sperm with proteins synthesized and secreted by
the epithelium but also on the proper maintenance of the epididymal luminal milieu as a whole. Much emphasis has
been placed on understanding the role of particular epididymal secretory proteins in the sperm maturation process
ultimately to provide new therapies for infertile couples as well as to identify targets for the development of male
contraceptives. Less is known, however, regarding the molecular mechanisms that contribute to the overall
maintenance of the luminal compartment, including mechanisms to remove secretory proteins selectively as well as those to
manage potential problems that can arise from proteins that do not
maintain their native structures following secretion
into the extracellular space. Because the maturation of spermatozoa is critical for perpetuation of the species, it is likely
that surveillance/quality control mechanisms are in place in the epididymal lumen to protect against potential cytotoxicity
of protein misfolding and aggregation and to allow maturation to occur. However, to date, the mechanisms of protein
aggregation, biological significance, and mechanisms for control/removal of protein aggregates in the epididymis are
not known. Understanding the mechanisms of extracellular quality control in the epididymal lumen can have
far-reaching implications not only for identifying conditions that could contribute to infertility but also will provide new
therapies for diseases of extracellular protein aggregation, including Alzheimer's disease, type II diabetes and
Creutzfeldt-Jakob disease.
Our laboratory studies the cystatin family of
cysteine protease inhibitors, including the members cystatin
C and cystatin-related epididymal spermatogenic (CRES)
protein and their roles in epididymal and sperm function.
On the basis of their inherent propensity to aggregate,
we initiated studies to examine protein aggregation in the
epididymal lumen using CRES and cystatin C as
molecular models. In this chapter, we will first present a
background of what is known from other organ systems
regarding quality control mechanisms for misfolded and
aggregated proteins, mechanisms of protein aggregation
with an emphasis on the amyloidogenic pathway, and a
brief review of our molecular models. We will then
present a summary of our studies of CRES
oligomerization in the epididymis, including studies that might
identify a mechanism for extracellular quality control.
2 Intracellular and extracellular quality control
Correct protein folding is essential for normal
biological function of all organisms. Genetic mutations that
can result in a destabilized protein or environmental
conditions that promote protein misfolding can lead to
cytotoxic protein aggregates associated with numerous
disease states, including Alzheimer's, Parkinson's,
Huntington's, Creutzfeldt-Jakob disease, type 2 diabetes
and cerebral amyloid angiopathy. Prokaryotic and
eukaryotic cells use post-translational quality control
systems to repair or remove the misfolded proteins. Indeed,
the fate of misfolded intracellular proteins is well-studied
and includes rescue by chaperones, destruction by proteases, and aggregation. More specifically, chaperones,
such as heat shock proteins Hsp90, Hsp70 and Hsp60 are
thought to facilitate the correct folding of non-native
proteins [1], whereas other chaperones, such as Hsp25 and
α-crystallin, bind to exposed hydrophobic regions on
unfolded proteins and prevent aggregation until other
chaperones can bind [2, 3]. Degradation of misfolded
intracellular proteins primarily occurs in the cytosolic
proteosome, which degrades proteins that are tagged by
ubiquitin in the ER and cytosol. The ER does not,
however, catch all misfolded proteins because very
recent reports describe the secretion of misfolded transthyretin,
suggesting that protein energetics, rather than strict quality
control, dictates extent of export from the ER [4].
Once proteins are secreted, they enter the extracellular space in
which mechanisms of folding control have yet to be
discovered in any organ system. Several studies support the
view that extracellular quality control mechanisms exist,
including studies showing that denatured plasma proteins
are catabolized in vivo more rapidly than native
counterparts [3, 5]. Although mechanisms similar to
intracellular quality control are possible, to date intracellular
chaperones have been detected only at low levels in
extracellular spaces [3]. Current evidence also does not
support a major role for the ubiquitin/proteosome pathway
in extracellular quality control, although it is of interest
that ubiquitin is present in the epididymal lumen
associated with epididymosomes [6, 7]. In general, exposed
hydrophobicity in proteins is thought to be the structural
change that signals quality control intervention. Studies
of extracellular chaperones clusterin and haptoglobin
indicate that they recognize hydrophobicity and form
non-covalent complexes with non-native proteins and
prevent their aggregation, suggesting that these molecules
might function as part of an extracellular quality control
mechanism [3, 8]. Furthermore, there is a precedent that
by forming a complex with non-native proteins,
extracellular chaperones can mediate the uptake of their ligands
via cell-surface receptors and direct them for
intracellular degradation [3]. If indeed extracellular quality
control mechanisms exist, then it is likely that a dysfunction
of this system could lead to diseases of misfolded
proteins. Therefore, defining the mechanisms of
extracellular quality control in the epididymis is of high
significance not only for reproductive function and
treatment of infertility but also could have broad implications
for diseases of extracellular protein misfolding, such as
Alzheimer's disease, type II diabetes and cerebral
angiopathies.
3 Amyloid-type protein aggregation
Proteins can aggregate by several distinct pathways.
Nonspecific interactions between proteins in many
different conformations can result in the formation of
amorphous aggregate structures. Aggregation by the
amyloid pathway involves the specific interaction of
proteins with a defined intermediate structure ultimately
resulting in a higher ordered fibril. The abnormal
accumulation of aggregated protein generated by the
amyloid pathway is a common feature of degenerative
diseases. Aggregated amyloid-β protein is implicated in
Alzheimer's disease, whereas an accumulation of aggregated
α-synuclein is associated with Parkinson's disease.
Cystatin C forms amyloid in the cerebral arteries of patients with amyloid angiopathy.
In addition to neurodegenerative diseases, the presence of amyloid
in the testis and epididymis has been implicated in
human infertility [9, 10]. In most of these diseases, the
end-stage product that accumulates is amyloid fibrils.
These structures have been defined by their ability to
bind dyes such as Congo red and thioflavin, morphologically as
6_10 nm filaments, and structurally as "cross
β" fibrils by X-ray diffraction. It is of interest
that amyloid with these characteristic structures can
form from unrelated proteins, suggesting that they share
a common structural motif and aggregation pathway.
Proteins that have inherent properties for amyloid
formation are characterized by a high degree of
incompletely solvated backbone H bonds (not protected from
water attack), making them vulnerable and, therefore
sites of structural weakness [11, 12]. Proteins that fall
into this category include known disease-associated
proteins, such as amyloid β, α-synuclein, insulin,
cystatins and prion proteins [11, 12]. Once destabilized,
the protein will self-assemble into higher order structures, including noncovalent dimers, trimers,
tetramers, and oligomers that can be up to, or greater
than, 1 000 000 daltons. Based on techniques
including negative stain electron microscopy and atomic force
microscopy, studies of amyloidogenic proteins indicate
a common pathway for aggregation. The earliest
structures identified by these techniques are spherical
particles (3_25 nm in diameter) known as soluble oligomers,
which then form a beaded appearance known as a protofibril and, finally, the structures anneal to form
mature amyloid fibrils [13]. These mature amyloid fibrils
may then continue to grow by the addition of
destabilized monomers. The recent development of
conformation-dependent antibodies that specifically recognize
early-stage [14] and late-stage soluble oligomers [15],
and fibrillar forms [16] but not monomeric forms or
proteins in native conformations has provided valuable
reagents for study of these structures independent of
peptide sequence.
Although previously the amyloid fibrils were thought
to be the causative form in disease, a large number of
studies now indicate that the soluble oligomeric or
protofibrillar forms are cytotoxic and cause the disease
[13]. Because unrelated amyloidogenic proteins as well
as proteins not associated with disease can adopt
similar cytotoxic structures, one line of thought is that
protein structure rather than sequence is responsible for
the cellular toxicity [17]. Alternatively, a disruption of
the equilibrium between monomeric and oligomeric forms of a protein might cause pathologies because of
decreased monomer or new functions of the aggregated
protein. Nevertheless, it appears that protein
aggregation is more widespread than previously thought and
that organisms have developed mechanisms to protect
against amyloidogenesis. Currently, studies in the
amyloid field are focused on identifying the mechanisms of
soluble oligomer-induced cellular toxicity and evidence
suggests a disruption of the cell membrane, possibly
by the formation of permeable channels, and subsequent calcium dysregulation and apoptosis leading to
cell death [18, 19].
4 Transglutaminases (TGase)
Transglutaminases (TGases) are a family of
calcium-dependent enzymes that catalyze γ-glutamyl-amine
cross-links between reactive glutamine and lysine residues
resulting in a covalent bond resistant to denaturation.
TGase-mediated isopeptide bonds can form between two
distinct proteins with one protein contributing the
glutamine and the other the lysine, or result in the
cross-linking of amines, such as polyamines or the fluorescent
tag monodansylcadaverine, to proteins with reactive
glutamine residues. Complete TGase substrates in which
one protein has both the reactive glutamine and lysine
residues are rarer but can result in both intramolecular
and intermolecular cross-links. Nine TGase genes have
been identified, eight of which encode active enzymes.
TGase are members of the papain family of cysteine
proteases and are highly conserved at their active site.
TGase2 or tissue-type TGase (tTGase) is perhaps the
most-studied family member and is present both
intracellularly and extracellularly in many tissues, including
the testis and epididymis. Although tTGase has been
implicated in cell proliferation, differentiation and
apoptosis, its functions remain enigmatic. It has been
proposed that tTGase functions might vary depending
on its tissue and cellular localization [20]. In particular,
the presence of different accessible proteins to act as
tTGase substrates might determine its cell
type-dependent activity and function. In support of this, several
studies have suggested a role for tTGase in stabilizing
protein aggregates, therefore contributing to diseases
such as in Alzheimer's disease [21, 22], whereas other
reports suggest a protective effect of tTGase by virtue
of its forming protein cross-links and, therefore, protein
aggregates in a nontoxic conformation distinct from that
in a disease-related oligomer [23, 24]. By diverting
protein aggregates from the amyloid pathway, nontoxic
aggregate structures may then be targeted for endocytosis.
This hypothesis is supported by studies showing that
TGase is involved in receptor-mediated endocytosis [26].
Although studies proposing a protective effect of tTGase
on protein aggregation were carried out by examining
intracellular amyloidogenic proteins [25], tTGase is also
present extracellularly and as such may perform similar
functions as a means of extracellular quality control,
including within the epididymis. Although TGases in
general have proposed roles in reproduction, including
sperm motility [27] and formation of the seminal
coagulum [28], tTGase knockout mice are viable and fertile
[29, 30]. Redundancy among TGase family members is
thought to contribute to the lack of a defined phenotype.
However, whether the tissue-type TGase activity in the
testis and epididymis represents the same tTGase gene
product that was knocked out is not known, nor have
detailed studies of reproductive function in the tTGase
knockout mice been carried out.
5 Epididymal luminal environment
The epididymis consists of a single long convoluted
tubule through which spermatozoa must pass following
their release from the testis. Testicular spermatozoa are
nonfunctional in that they lack progressive motility and
the ability to fertilize and only acquire these functions
after undergoing sperm maturation in the epididymis.
Because sperm are synthetically inactive, the maturation
process involves the interaction of sperm with proteins
that are synthesized and secreted by the epididymal
epithelium. Epididymal protein synthesis and secretion
is highly regionalized such that proteins expressed and
secreted in one region of the tubule may not be expressed
in adjacent regions. In addition to active protein
secretion into the epididymal lumen, other proteins are removed.
Although the mechanisms of protein removal from the
lumen are not well-understood, the epithelium has been
shown to carry out fluid phase, adsorptive and
receptor-mediated endocytosis [31]. Together, region-dependent
protein secretion and reabsorption by the epithelium result
in spermatozoa encountering an ever-changing luminal
environment as they migrate from the caput to the cauda
region, which ultimately results in sperm
maturation.
By far the majority of studies in the epididymis have
focused on identifying specific epididymal secretory
proteins and their functional roles in sperm maturation
ultimately to identify novel targets for male contraception
or to provide new treatments for male infertility.
However, equally important as these individual proteins,
is understanding the complex epididymal luminal milieu
as a whole because perturbations in the
microenvironment that surrounds the sperm cell could affect
maturation. The epididymal lumen contains perhaps the
most complex fluid found in any exocrine gland
resulting from the continuous changes in composition, as
previously mentioned, as well as the presence of
components in unusual concentrations (for reasons not yet
known), or those not present in other body fluids [32].
The caput epididymidis, the region the spermatozoa first
enter coming from the testis/efferent ducts, is the most
metabolically active region, secreting 70_80% of the
total overall protein secretion in the epididymal lumen [32].
Moreover, within this same region, 99% of the fluid
accompanying the testicular sperm is resorbed,
resulting not only in a profound concentration of
spermatozoa but luminal components as well [33]. Although
such an environment might be integral for sperm maturation, an environment low in water content
creates a situation of macromolecular crowding, which
places unique stresses on luminal proteins that can
alter their behavior and lead to protein misfolding and
aggregation [34, 35]. Other stressors, such as
inappropriate ionic strength, oxidative stress, and pH and
temperature extremes, are also known to promote the
unfolding of fully folded native proteins and the
formation of aggregated proteins, which can be cytotoxic.
Considering that this same epididymal environment must protect spermatozoa and allow maturation, it is
likely that mechanisms are in place to prevent or
remove aggregated proteins. However, to date,
virtually nothing is known regarding protein aggregation in
the epididymal lumen, including mechanism of formation, biological significance, and mechanisms for
control and/or removal.
Several recently published reports provide evidence
that the epididymal fluid does not just consist of a large
pool of soluble proteins in their native conformations,
but rather also contains proteinaceous aggregate
structures of varying molecular mass. In particular, the
amyloidogenic prion protein is present in the epididymal
lumen both in insoluble exosome-like membranous vesicles (epididymosomes) [36], and in a soluble high
molecular mass lipophilic complex in association with
hydrophobic proteins [37]. The chaperone clusterin,
which is known to interact with hydrophobic proteins to
maintain their solubility, was also detected in the soluble
prion protein complex. This suggests that these
structures might be a means to maintain proteins in their soluble
state either to prevent aggregation and precipitation and
to enable clearance or to allow hydrophobic proteins to
be transferred between cells, such as the epididymal
epithelium and spermatozoa. Although still not
well-characterized, the epididymosomes are small
membrane-bound vesicles in the lumen that are thought to arise from
apocrine type secretion from the epithelium and to be a
means to transfer hydrophobic proteins to the maturing
sperm cells [38, 39].
Other evidence for the presence of protein aggregates
in the epididymal lumen comes from studies examining
molecular chaperones in the reproductive tract. Both heat
shock protein 1 (HSPD1, HSP60) and tumor rejection
antigen 1 (TRA1, a member of the heat shock protein 90
family) colocalize to large electron dense bodies in the
epididymal lumen. These structures seemed not to be
membrane bound and are larger than epididymosomes,
suggesting unique structures [40]. Because proposed
functions of TRA1 include the folding of denatured
proteins as well as multimer assembly [41], its function in
the epididymal lumen might be as a means of
extracellular quality control, specifically to refold proteins in
non-native conformations or alternatively to facilitate
clearance. Most interesting is that TRA1, as well as other
heat shock family members, are substrates of TGase
cross-linking [20]. These data support the possibility
that TGase might participate in the removal of protein
aggregates from the epididymal lumen. Also of interest
is that the extracellular chaperone, clusterin, is abundantly
secreted in the epididymis of many species and
contributes an amazing 41% of the total protein secreted in the
rat caput epididymidis, suggesting an important role for
this protein in epididymal function, possibly as a
mediator of extracellular quality control [32]. Finally, there is
tantalizing evidence from other reports describing a dense,
filamentous material in the epididymis, which might also
represent protein aggregation [42].
Taken together, these studies suggest that protein
aggregation is an integral part of normal epididymal function
because there appear to be no obvious detrimental effects
of these structures on the maturation of spermatozoa.
It is likely that in the epididymal lumen there is a delicate
equilibrium between proteins in monomeric and aggregate
states and that mechanisms for controlling/neutralizing
potentially cytotoxic aggregates are in place. Indeed, the
presence of chaperone proteins, some of which are transglutaminase substrates, in most of the aggregate
structures identified thus far support this interpretation.
6 Cystatins and the L68Q cystatin C mutation
The cystatins are a superfamily of tight binding but
reversible cysteine protease inhibitors consisting of three
families: stefins, cystatins and kininogens [43]. The family
2 cystatins, represented by cystatin C, are small (14_16
kDa) secretory proteins. Although it is well-established
by in vitro studies that the cystatins are potent cysteine
protease inhibitors, their in vivo functions are less clear.
Because of its amyloidogenic properties, cystatin C is
implicated in several diseases. Notably, cystatin C
contributes to protein deposits in cerebral arteries of patients
with age-related cerebral amyloid angiopathy, including
that associated with Alzheimer's disease [44], whereas
in the hereditary form of the disease a point mutation
(L68Q) leads to a destabilized and, therefore, highly
amyloidogenic form of cystatin C that forms protein
deposits in patients who die before age 30 of hemorrhagic
stroke [45]. Detailed studies of cystatin C
oligomerization showed that it forms dimers by the process of 3-D
domain swapping and as such is inactive as a cysteine
protease inhibitor [46]. Studies of cystatin C protein
aggregation are important for information that can be
gained regarding the biological consequences of, or
mechanisms by which, cystatin C aggregation may be prevented
and would ultimately be beneficial for diseases associated
with these processes. Because of its causative role in
neurodegenerative diseases, little attention has been paid
to its putative role in reproduction and, in fact, little is
known regarding cystatin C in the reproductive tract other
than localization in Sertoli cells [47], germ cells [47] and
the epididymis [48] and that cystatin C knockout mice are
fertile [49]. Whether male individuals with the hereditary
form of cystatin C angiopathy (L68Q) exhibit subfertility
or infertility is not known, likely as a result of the fact that
most individuals die early in life and probably before
attempting to father children. However, in L68Q patients,
cystatin C amyloid has been detected in tissues outside of
the brain, including in the testis [50].
7 CRES
CRES is the defining member of a new subgroup within the family 2 cystatins [48, 51]. Although sequence,
predicted structure, and chromosomal mapping data
indicate that CRES is a secretory cystatin, it is distinct
from the typical cystatins by its reproductive-specific
expression and lack of conserved sites necessary for
cysteine protease inhibition, predicting distinct
biochemical activities. Indeed, our in
vitro studies showed that CRES did not inhibit cysteine proteases but rather
inhibited prohormone convertases, specifically PC2, a
substrate-specific serine protease that processes precursor
hormones/proteins to their mature and active forms [52].
Therefore, one role for CRES might be to mediate proprotein processing events. Within the epididymis,
CRES is synthesized and secreted by the proximal caput
epididymal epithelium, accumulates in the lumen of the
midcaput, but abruptly disappears from the distal caput
epididymal lumen [53]. The mechanism(s) for the
sudden disappearance of CRES is not known. Because most
pro-hormone convertases function within the secretory
pathway, it is possible that CRES function might also be
intracellular, specifically within the secretory granule.
Therefore, its presence in the epididymal lumen might
merely be a result of its being part of the secretory
granule contents that are released upon secretion and, as such,
may then be targeted for removal.
Throughout our years of study with CRES we observed that it had a high propensity to self-aggregate in
all types of expression systems, including bacterial
expression, secretion from Pichia pastoris, and in
in vitro transcription and translation. Using the PoPMuSiC
algorithm that predicts protein instabilities and likelihood to
self-aggregate [54], CRES showed sites of incompletely
solvated H bonds (i.e. structural weakness that were
located in similar positions to that in cystatin C). That
crystallography showed these regions in cystatin C to be
sites of local unfolding, and subsequent refolding in a
dimeric state supports the view that CRES might
self-aggregate by a similar mechanism [46]. Furthermore,
cystatin C dimer formation was shown to be the first
step in the pathway towards amyloid formation [55], also
implying CRES potential for amyloidogenesis.
8 CRES oligmerization in the epididymal lumen
Studies were initiated to determine whether CRES
forms oligomeric structures in vivo on the basis of two
observations. First, we were intrigued by the abrupt and
complete disappearance of CRES from the caput epididymal lumen [53]. Although we can not rule out that
other mechanisms such as proteolytic degradation or
endocytosis are involved, the lack of data supporting these
processes as the sole means of CRES disappearance prompted us to consider other possible mechanisms.
Because cystatin C, as well as several other cystatins,
had been shown to self-aggregate we questioned whether
CRES could also self-aggregate and considered that
perhaps our inability to detect CRES in the lumen of regions
downstream of the midcaput could be due to its
presence in high molecular mass oligomeric structures.
Using size exclusion chromatography to fractionate caput
luminal fluid followed by Western blot analysis, we
determined that a proportion of CRES was detected in the
void volume, suggesting its presence in high molecular
mass structures. The use of the homo-bifunctional
sulfhydryl reversible chemical cross-linker DSP allowed us
to trap CRES heterodimeric and oligomeric structures
that were reversed to the 19 and 14 kDa CRES monomers in the presence of reducing agents. These studies
suggested that the high molecular mass structures represent, in part, self-aggregates of CRES. Further
studies of caput fluid using size exclusion chromatography
and SDS-agarose gels allowed us to detect high
molecular mass CRES oligomeric structures that were resistant
to SDS. Taken together, there studies revealed that CRES
was present in the caput epididymidal lumen in multiple
forms, including soluble SDS-resistant and
SDS-sensitive oligomeric structures, as well as in monomeric forms.
Size exclusion chromatography and Western blot
analysis of luminal fluid from all regions of the epididymis
showed the presence of SDS-resistant CRES oligomeric
structures in the proximal caput region, an accumulation
in the midcaput, and a continued presence in the distal
caput region. Monomeric CRES, however, was only detected in the proximal and mid-caput regions. This
suggests that the "disappearance" of CRES from the
epididymal lumen might indeed reflect its association with
high molecular mass structures, which might be less
antigenic and difficult to detect by
immunohistochemistry and not resolved on standard SDS-PAGE gels used in
our initial studies to examine CRES protein.
9 Mechanism of CRES protein aggregation
Studies were next carried out to determine the
molecular mechanism of CRES protein aggregation. Because
cystatin C is known to form amyloid in several disease
conditions, we determined whether CRES might aggregate by the amyloidogenic pathway. Recombinant CRES
protein incubated for extended times at 37ºC was
examined by negative stain electron microscopy. These
studies showed that over time CRES formed soluble
oligomers and protofibrils typical of amyloidogenic proteins.
Furthermore, after several days of incubation CRES
formed fibrils that stained with Congo red, a
conformation-dependent dye that is used clinically to diagnose
amyloid. These studies demonstrate that in
vitro CRES aggregates by the amyloidogenic pathway and studies
are in progress to determine whether CRES aggregates
in vivo are also by this process.
10 CRES is a substrate for TGase
Because a proportion of oligomeric CRES in the caput
fluid was present in SDS-resistant high molecular mass
structures, we next examined the potential mechanism for
formation of the stable oligomeric structures.
TGase are known to form stable cross-links that are resistant to
denaturation between glutamine and lysine residues. Therefore,
experiments were carried out to determine whether TGase
cross-linking could be involved in the formation of stable
CRES oligomers. Incubation of recombinant CRES
protein with guinea pig liver TGase, calcium and the
fluorescent amine monodansylcadaverine (MDC) resulted in a
time-dependent fluorescent labeling of CRES protein that was
inhibited by the presence of EDTA and TGase inhibitors.
These studies indicated that CRES had reactive glutamine
sites that were substrates for TGase cross-linking.
Additional studies in which CRES was incubated with TGase
but without MDC demonstrated a time-dependent
disappearance of the CRES monomer that was prevented by
the addition of TGase inhibitors. These studies suggest
that CRES is a complete TGase substrate and contains
both reactive glutamine and lysine residues that are
substrates for TGase and that following exposure to TGase
CRES will form high molecular mass oligomeric
structures that do not enter a typical SDS-PAGE gel.
Additional studies including 14C-putrescine incorporation
assays showed the presence of TGase activity within the
epididymal lumen with highest activities in the proximal
caput region and that endogenous CRES is a substrate
for both exogenous and endogenous TGase cross-linking and will form SDS-stable high molecular mass
oligomers in the caput fluid. To determine whether TGase
cross-linking of CRES altered its conformation, CRES
was incubated with guinea pig liver TGase and examined
by negative stain electron microscopy. These
experiments showed that TGase cross-linking caused CRES
to form an amorphous protein aggregate distinct from
the highly organized oligomeric structures of the amyloidogenic pathway. Therefore, TGase
cross-linking might divert CRES from the potentially cytotoxic
amyloidogenic pathway and instead form aggregates that
are nontoxic.
11 Summary
We propose that the formation of protein aggregates
is a natural process occurring within the epididymal
lumen. Because these protein structures can be
cytotoxic either by a mechanical disruption and/or properties
inherent in their oligomeric structures, the epididymis
utilizes extracellular quality control mechanisms to
protect sperm maturation and epididymal cell function.
Although extracellular control mechanisms have not yet
been described in any organ system, the presence of
significant amounts of transglutaminase activity and
extremely high levels of clusterin in the epididymal fluid,
suggest that protein cross-linking and chaperones might
be functioning either independently or synergistically to
control protein aggregation in the lumen. The
epididymal tubule and its luminal compartment are like no other
extracellular environment in the body in that sperm
maturation must occur despite a surrounding environment that
favors protein misfolding and aggregation. The unusual
composition and extraordinary levels of some components in the epididymal fluid might represent an
extracellular environment that has gone to extreme measures to
control problems/toxicities that are known to exist with
aggregate structures. It is also quite possible that once
formed oligomeric structures carry out biological
functions within the lumen.
Acknowledgment
Supported by National Institutes of Health/National
Institures of Child Health & Human Development
(HD3303, HD44669, USA) to Gail A. Cornwall.
References
1 Fink AL. Chaperone-mediated protein folding. Physiol Rev 1999;
79: 425_49.
2 Bross P, Corydon TJ, Andresen BS, Jorgensen MM, Bolund L,
Gregersen N. Protein misfolding and degradation in genetic
diseases. Human Mut 1999; 14: 186_98.
3 Yerbury JL, Stewart EM, Wyatt AR, Wilson MR. Quality control
of protein folding in extracellular space. EMBO Report 2005; 6:
1131_6.
4 Sekijima Y, Wiseman RL, Matteson J, Hammarstrom P, Miller
SR, Sawkar AR, et al. The biological and chemical basis for
tissue-selective amyloid disease. Cell 2005; 121: 73_85.
5 Margineau I, Ghetie V. A selective model of plasma protein
catabolism. J Theor Biol 1981; 90: 101_10.
6 Fraile B, Martin R, de Miguel MP, Arenas MI, Bethencourt FR,
Peinado F, et al. Light and electron microscopic
immunohistochemical localization of protein gene product 9.5 and ubiquitin
immunoreactivities in the human epididymis and vas deferens.
Biol Reprod 1996; 55: 291_7.
7 Sutovsky P, Moreno R, Ramalho-Santos J, Dominko T,
Thompson WE, Schatten G. A putative, ubiquitin-dependent mechanism
for the recognition and elimination of defective spermatozoa in
the mammalian epididymis. J Cell Sci 2001; 114: 1665_75.
8 Humphreys D, Carver JA, Easterbrook-Smith SB, Wilson MR.
Clusterin has chaperone-like activity similar to that of small
heat-shock proteins. J Biol Chem 1999; 274: 6875_81.
9 Nistal M, Paniagua R, Picazo ML. Testicular and epididymal
involvement in Fabry's disease. J Path 1983; 141: 113_24.
10 Haimov-Kochman, Prus D, Ben-Chetrit E. Azoospermia due to
testicular amyloidosis in a patient with familial Mediterranean
fever. Human Reprod 2001; 16: 1218_20.
11 Fernandez A, Kardos J, Scott LR, Goto Y, Berry RS. Structural
defects and the diagnosis of amyloidogenic propensity. Proc
Natl Acad Sci USA 2003; 100: 6446_51.
12 Fernandez A, Berry RS. Proteins with H-bond packing defects are
highly interactive with lipid bilayers: implications for
amyloidogenesis. Proc Natl Acad Sci U S A 2003; 100: 2391_6.
13 Glabe CG. Conformation-dependent antibodies target diseases of
protein misfolding. Trends Biochem Sci 2004; 29: 542_7.
14 Oddo S, Caccamo A, Tran L, Lambert MP, Glabe CG, Klein WL,
et al. Temporal profile of amyloid-beta (Abeta) oligomerization
in an in vivo model of Alzheimer disease. J Biol Chem 2006; 281:
1599_604.
15 Kayed R, Head E, Thompson JL, McIntire TM, Milton SC,
Cotman CW, et al. Common structure of soluble amyloid
oligomers implies common mechanism of pathogenesis. Science 2003;
300: 486_9.
16 O'Nuallain B, Wetzel R. Conformational Abs recognizing a
generic amyloid fibril epitope. Proc Natl Acad Sci U S A 2002; 99:
1485_90.
17 Bucciantini M, Giannoni E, Chiti F, Baroni F, Formigli L, Zurdo
J, et al. Inherent toxicity of aggregates implies a common
mechanism for protein misfolding diseases. Nature 2002; 416: 507_11.
18 Demuro A, Mina E, Kayed R, Milton SC, Parker I, Glabe CG.
Calcium dysregulation and membrane disruption as a ubiquitous
neurotoxic mechanism of soluble amyloid oligomers. J Biol Chem
2005; 280: 17294_300.
19 Singer SJ, Dewji NN. Evidence that Perutz's double-beta-stranded
subunit structure for beta-amyloids also applies to their
channel-forming structures in membranes. Proc Natl Acad Sci U S A 2006;
103: 1546_50.
20 Orru S, Caputo I, D'Amato A, Ruoppolo M, Esposito C. Proteomics
identification of acyl-receptor and acyl-donor substrates for
transglutaminase in a human intestinal epithelial cell line:
implications for celiac disease. J Biol Chem 2003; 278: 31766_73.
21 Boros S, Kamps B, Wunderink L, de Bruijn W, de Jong WW,
Boelens WC. Transglutaminase catalyzes differential crosslinking
of small heat shock proteins and amyloid-beta. FEBS Lett 2004;
576: 57_62.
22 Dudek SM, Johnson GV. Transglutaminase catalyzes the
formation of sodium dodecyl sulfate-insoluble Alz-50-reactive
polymers of tau. J Neurochem 1993; 61: 1159_62.
23 Karpu MV, Garren H, Slunt H, Price DL, Gusella J, Becher MW,
et al. Transglutaminase aggregates huntingtin into nonamyloidogenic
polymers, and its enzymatic activity increases in Huntington's
disease brain nuclei. Proc Natl Acad Sci U S A 1999; 96: 7388_93.
24 Konno T, Morii T, Hirata A, Sato SI, Oiki S, Ikura K. Covalent
blocking of fibril formation and aggregation of intracellular
amyloidogenic proteins by transglutaminase-catalyzed
intramolecular cross-linking. Biochemistry 2005; 44: 2072_9.
25 Konno T, Morii T, Shimizu H, Oiki S, Ikura K. Paradoxical
inhibition of protein aggregation and precipitation by
transglutaminase-catalyzed intermolecular crosslinking. J Biol Chem 2005; 280:
17520_5.
26 Levitzki A, Willingham M, Pastan I. Evidence for participation
of transglutaminase in receptor-mediated endocytosis. Proc Natl
Acad Sci U S A 1980; 77: 2706_10.
27 de Lamirande E, Gagnon C. Effects of transglutaminase
substrates and inhibitors on the motility of demembranated
reactivated sperm. Gamete Res 1989; 22: 179_92.
28 Peter A, Lilja H, Lundwall A, Malm J. Semenogelin I and semenogelin
II, the major gel-forming proteins in semen, are substrates for
transglutaminase. Eur J Biochem 1998; 252: 216_21.
29 De Laurenzi V, Melino G. Gene disruption of tissue transglutaminase.
Mol Cell Biol 2001; 21: 148_55.
30 Nanda N, Iismaa SE, Owens WA, Husain A, Mackay F, Graham
RM. Targeted inactivation of Gh/tissue transglutaminase II. J
Biol Chem 2001; 276: 20673_8.
31 Andonian S, Hermo L. Cell- and region-specific localization of
lysosomal and secretory proteins and endocytic receptors in
epithelial cells of the cauda epididymidis and vas deferens of the
adult rat. J Androl 1999; 20: 415_29.
32 Dacheux JL, Dacheux F. Protein secretion in the epididymis. In:
Robaire B, Hinton B, editors. The Epididymis: From Molecules
to Clinical Practice. New York: Kluwer Academic/Plenum
Publishers; 2002: 151_68.
33 Mann T, Lutwak-Mann C. Male Reproductive Function and
Semen. Heideberg: Springer-Verlag; 1982: 139_59.
34 Rialdi G, Battistel E. Thermodynamics of proteins in unusual
environments. Biophys Chem 2007; 126: 64_79.
35 Minton AP. Influences of macromolecular crowding on upon the
stability and state of association of proteins:predictions and
observations. J Pharm Sci 2005; 94: 1668_75.
36 Ecroyd H, Sarradin P. Dacheux JL, Gatti JL.
Compartmentalization of prion isoforms within the reproductive tract of the ram.
Biol Reprod 2004; 71: 993_1001.
37 Ecroyd H, Belghaz M, Dacheux JL, Gatti JL. The epididymal soluble
prion protein forms a high molecular-mass complex in association
with hydrophobic proteins. Biochem J 2005; 392: 211_9.
38 Sullivan R, Saez F, Girouard J, Frenette G. Role of exosomes in
sperm maturation during the transit along the male reproductive
tract. Blood Cells Mol Dis 2005; 35: 1_10.
39 Rejraji H, Sion B, Prensier G, Carreras M, Motta C, Frenoux JM,
et al. Lipid remodeling of murine epididymosomes and spermatozoa
during epididymal maturation. Biol Reprod 2006; 74: 1104_13.
40 Asquith KL, Harman AJ, McLaughlin EA, Nixon B, Aitken RJ.
Localization and significance of molecular chaperones, heat shock
protein 1, and tumor rejection antigen gp96 in the male
reproductive tract and during capacitation and acrosome reaction.
Biol Reprod 2005; 72: 328_37.
41 Nigam SK, Goldberg AL, Ho S, Rohde MF, Bush KT, Sherman
MY. A set of endoplasmic reticulum proteins possessing
properties of molecular chaperones includes
Ca2+-binding proteins and members of the thioredoxin superfamily. J Biol Chem 1994;
269: 1744_9.
42 Cooper TG, Hamilton DW. Observations on the destruction of
spermatozoa in the cauda epididymidis and proximal vas deferens
of nonseasonal male mammals. Am J Anat 1977; 149: 93_110.
43 Barrett AJ. The cystatins: a diverse superfamily of cysteine
peptidase inhibitors. Biomed Biochim Acta 1986; 45: 1363_74.
44 Levy E, Sastre M, Kumar A, Gallo G, Piccardo P, Ghetti B,
et al. Codeposition of cystatin C with amyloid beta protein in the
brain of Alzheimer disease patients. J Neuropath Exp Neurol
2001; 60: 94_104.
45 Olafsson I, Grubb A. Hereditary cystatin C amyloid angiopathy.
Amyloid 2000; 7: 70_9.
46 Janowski R, Kozak M, Jankowska E, Grzonka Z, Grubb A,
Abrahamson M, et al. Human cystatin C, an amyloidogenic
protein, dimerizes by through three dimensional domain swapping.
Nat Struct Biol 2001; 8: 316_20.
47 Tsuruta JK, O'Brien DA, Griswold MD. Sertoli cell and germ cell
cystatin C: stage-dependent expression of two distinct
messenger ribonucleic acid transcripts in rat testes. Biol Reprod 1993;
49: 1045_54.
48 Cornwall GA, Orgebin-Crist MC, Hann SR. The
CRES gene: a unique testis-regulated gene related to the cystatins is highly
restricted in its expression to the proximal region of the mouse
epididymis. Mol Endocrinol 1992; 6: 1653_64.
49 Huh CG, Hakansson K, Nathanson CM, Thorgeirsson UP, Jonsson
N, Grubb A, et al. Decreased metastatic spread in mice
homozygous for a null allele of the cystatin C protease inhibitor gene.
Mol Pathol 1999; 52: 332_40.
50 Palsdottir A, Snorradottir AO, Thorsteinsson L. Hereditary
cystatin C amyloid angiopathy: genetic, clinical, and
pathological aspects. Brain Pathol 2006; 16: 55_9.
51 Cornwall GA, Hsia N. A new subgroup of the family 2 cystatins.
Mol Cell Endocrinol 2003; 200: 1_8.
52 Cornwall GA, Cameron AG, Lindberg I, Hardy DM, Cormier N,
Hsia N. The cystatin-related epididymal spermatogenic protein
inhibits the serine protease prohormone convertase 2. Endocrinol
2003; 144: 901_8.
53 Cornwall GA, Hann SR. Transient appearance of CRES protein
during spermatogenesis and caput epididymal sperm maturation.
Mol Reprod Dev 1995; 41: 37_46.
54 Dehouock Y, Biot C, Gilis D, Kwasigroch JM, Rooman M.
Sequence-structure signals of 3D domain swapping in proteins. J
Mol Biol 2003; 330: 1215_25.
55 Nilsson M, Wang X, Rodziewicz-Motowidlow S, Janowski P,
Lindstrom V, Onnerfjord P, et al. Prevention of domain
swapping inhibits dimerization and amyloid fibril formation of cystatin
C: use of engineered disulfide bonds, antibodies, and
carboxymethyl papain to stabilize the monomeric form of cystatin C. J
Biol Chem 2004; 279: 24236_45. |